{"title":"Gait phase recognition of children with cerebral palsy via deep learning based on IMU data from a soft ankle exoskeleton.","authors":"Zhi Pang, Zewei Li, Ying Li, Bingshan Hu, Qiu Wang, Hongliu Yu, Wujing Cao","doi":"10.3389/fbioe.2025.1679812","DOIUrl":null,"url":null,"abstract":"<p><p>Accurate gait-phase identification in children with Cerebral Palsy (CP) constitutes a pivotal prerequisite for evidence-based rehabilitation. Addressing the precise detection of gait disturbances under natural ambulation, we propose a deep-learning framework that integrates a stacked denoising autoencoder (SDA) with a long short-term memory network (SDA-LSTM) to classify four canonical gait phases. A community-oriented dataset was constructed by synchronizing ankle-mounted inertial measurement units (IMU) with plantar-pressure insoles; natural gait sequences of six children with mild CP were acquired in open environments. The SDA layer robustly extracts discriminative representations from non-stationary, high-noise signals, whereas the LSTM module models inter-phase temporal dependencies, thereby enhancing generalization cross-user. In noise-free conditions the SDA-LSTM framework attained 97.83% accuracy, significantly exceeding SVM (94.68%), random forest (96.05%), and standalone LSTM (95.86%). Under additive Gaussian noise with SNR ranging from 5 to 30 dB, the model preserved stable performance; at 10 dB SNR (Signal-to-Noise Ratio), accuracy remained 90.96%, corroborating its exceptional robustness. These findings demonstrate that SDA-LSTM effectively handles the complex, heterogeneous gait patterns of children with CP and is readily deployable for clinical assessment and exoskeletal assistance systems, indicating substantial translational potential.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1679812"},"PeriodicalIF":4.8000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457781/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1679812","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Accurate gait-phase identification in children with Cerebral Palsy (CP) constitutes a pivotal prerequisite for evidence-based rehabilitation. Addressing the precise detection of gait disturbances under natural ambulation, we propose a deep-learning framework that integrates a stacked denoising autoencoder (SDA) with a long short-term memory network (SDA-LSTM) to classify four canonical gait phases. A community-oriented dataset was constructed by synchronizing ankle-mounted inertial measurement units (IMU) with plantar-pressure insoles; natural gait sequences of six children with mild CP were acquired in open environments. The SDA layer robustly extracts discriminative representations from non-stationary, high-noise signals, whereas the LSTM module models inter-phase temporal dependencies, thereby enhancing generalization cross-user. In noise-free conditions the SDA-LSTM framework attained 97.83% accuracy, significantly exceeding SVM (94.68%), random forest (96.05%), and standalone LSTM (95.86%). Under additive Gaussian noise with SNR ranging from 5 to 30 dB, the model preserved stable performance; at 10 dB SNR (Signal-to-Noise Ratio), accuracy remained 90.96%, corroborating its exceptional robustness. These findings demonstrate that SDA-LSTM effectively handles the complex, heterogeneous gait patterns of children with CP and is readily deployable for clinical assessment and exoskeletal assistance systems, indicating substantial translational potential.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.